Orbis Allan Gray’s Puma Biotechnology PBYI Stock Holding History

Orbis Allan Gray’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-43,493	Closed	-$1.33M	–	71
2016 Q4	$1.33M	Hold	43,493	–	–	0.01%	63
2016 Q3	$2.92M	Sell	43,493 -361	-0.8%	-$18.3K	0.02%	72
2016 Q2	$1.31M	Hold	43,854	–	–	0.01%	71
2016 Q1	$1.29M	Buy	+43,854	New	+$1.98M	0.01%	76

Other funds holding PBYI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Orbis Allan Gray's PBYI Position: Q1 2017 in Review

Orbis Allan Gray sold out of Puma Biotechnology (PBYI) in Q1 2017, closing a stake of 43,493 shares — an estimated $1.33M sold.

Orbis Allan Gray first reported a position in PBYI in Q1 2016 and held it in 4 quarters. The position peaked at $2.92M in Q3 2016. 136 funds tracked by Wall St. Rank hold PBYI as of Q1 2017.

Orbis Allan Gray reported no remaining Puma Biotechnology position as of Q1 2017 after selling out during the quarter.
Orbis Allan Gray sold 43,493 Puma Biotechnology shares in Q1 2017, an estimated $1.33M.
Orbis Allan Gray first reported a position in Puma Biotechnology in Q1 2016 and held it in 4 quarters.
Orbis Allan Gray's Puma Biotechnology position peaked at $2.92M in Q3 2016.
136 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2017.

Based on Orbis Allan Gray's 13F filing for Q1 2017, filed 15 May 2017.